HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Trims Nutritional Drink Lines, Wants All Of Its Consumer JV Pie

This article was originally published in The Pink Sheet

Executive Summary

With its July 26 earnings report, the UK firm made clear it's ready to become sole owner of its consumer health JV with Novartis, and that divesting UK brands Horlicks and MaxiNutrition are among its steps toward cutting manufacturing costs.

You may also be interested in...



Consumer Business Reliable And Right At Home At GlaxoSmithKline

CEO Walmsley's familiarity with Glaxo's consumer health business was clear in her response to analysts' questions about the firm's future as a three-unit operation. The business marketing brands including Flonase and Excedrin is a more reliable revenue driver than the pharma business, she said.

Glaxo In Charge, And The World Is GSK/Novartis Consumer Product JV’s Oyster

GSK Consumer Healthcare not only is the name of Glaxo/Novartis JV, but also the brand being added to Novartis’ OTC products. The JV will access OTC switch opportunities across the Rx portfolios of both Glaxo and Novartis in addition to external partners, says Americas/Europe head Brian McNamara.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel